Search Reports:

Enter company name or symbol or keyword from report title or report description. You can also use our advanced search option to further filter your results.

Accuracy of Opinions

984 (79%) - Correct
255 (21%) - Incorrect

Explanation

Recent News on Covered Stocks

Reports

Cell Therapeutics, Inc. (CTIC) - Historical Event - January 19, 2012

Pixuvri for Multiple Relapsed Refractory Aggressive Non-Hodgkin's Lymphoma/NHL (CHMP Review)

CHMP review of Pixuvri (pixantrone) for the treatment of multiple relapsed refractory aggressive non-Hodgkin's lymphoma (NHL) 

- Price: $10.00      Add to cart       Mail to friend       Add to favorite

Back to list

Sample Report:

VRTX's HCV drug Telaprevir received FDA approval on May 23, 2011. New BioMedicine had issued a report on this event on May 3, 2011. To read more about the drug, the disease, the market, the competition, etc. access it at the link below.
 

Basket Reports:

Free Basket Reports

Specific theme-based reports at a value price
View Package

©Copyright 2012 New Bio Medicine, LLC. All Right Reserved.